|Table of Contents|

The value of neutrophil-to-lymphocyte ratio(NLR) in predicting the efficacy of advanced non-small cell lung cancer treated with immunotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 01
Page:
54-57
Research Field:
Publishing date:

Info

Title:
The value of neutrophil-to-lymphocyte ratio(NLR) in predicting the efficacy of advanced non-small cell lung cancer treated with immunotherapy
Author(s):
ZHANG Yi1; ZHU Zhengqiu2; XUE Jing2
1.Xuzhou Medical University，Jiangsu Xuzhou 221000,China;2.Department of Oncology,the Affiliated Hospital of Xuzhou Medical University，Jiangsu Xuzhou 221000,China.
Keywords:
non-small cell lung cancer; pembrolizumab; neutrophil-to-lymphocyte ratio; short-term effects
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2022.01.011
Abstract:
Objective:To evaluate the value of peripheral blood neutrophil-to-lymphocyte ratio(NLR) in evaluating the short-term effects of patients with advanced non-small cell lung cancer(NSCLC) treated with immunotherapy.Methods：From August 2018 to December 2019,a total of 60 patients with advanced NSCLC treated with pembrolizumab as second and further-line treatment were collected.Of these patients,receiver operating characteristic(ROC) curve analysis was used to confirm the cut-off value,and patients were stratified into NLR＜2.605 and NLR≥2.605 groups.The correlation between the NLR level was analysed.The dynamic change of NLR level before and after treatment and the short-time efficacy were analysed.The efficacy was evaluated by RECIST 1.1.Results：A total of 60 patients were included in the statistics.The number in NLR＜2.605 group had 41 patients and NLR≥2.605 group had 19 patients.For the 60 patients,basic data difference between the two groups had no statistical significance(P＞0.05).NLR＜2.605 group had superior disease control rate(82.9% vs 26.3%,P＜0.05).Patients with an 30% increase in NLR were associated with lower DCR compared with those with stable or decrease in NLR after two cycles.Conclusion：NLR is one of the biological makers indicating the prognosis of non-small cell lung cancer.Baseline NLR and NLR kinetics could be used as predictive marker for treatment with immunotherapy.

References:

[1]LI S,ZHOU K,WANG M,et al.Degree of pulmonary fissure completeness can predict postoperative cardiopulmonary complications and length of hospital stay in patients undergoing video-assisted thoracoscopic lobectomy for early-stage lung cancer［J］.Interactive Cardio Vascular and Thoracic Surgery,2018,26(1):25-33.
[2]SIEGEL RL,MILLER KD.Cancer statistics,2018［J］.CA:A Cancer Journal for Clinicians,2018,68(1):7-30.
[3]ETTINGER DS,AKERLEY W,BORGHAEI H,et al.Non-small cell lung cancer［J］.Journal of the National Comprehensive Cancer Network,2012,10(10):1236-1271.
[4]HORN L,SPIGEL DR,VOKES EE,et al.Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer:Two-year outcomes from two randomized,open-label,phase Ⅲ trials(CheckMate 017 and CheckMate 057)［J］.Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology,2017,35(35):3924.
[5]BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer［J］.The New England Journal of Medicine,2015,373(2):123-135.
[6]HAVEL JJ,CHOWELL D.The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy［J］.Nature Reviews Cancer,2019,19(3):133-150.
[7]MANTOVANI A,ALLAVENA P,SICA A.Cancer-relate inflammation［J］.Nature,2008,454(7203):436-444.
[8]XIE X,LIU J,YANG H,et al.Prognostic value of baseline neutrophil-to-lymphocyte ratio in outcome of immune checkpoint inhibitors［J］.Cancer Investigation,2019,37(6):265-274.
[9]WANG Z,ZHAN P,LYU Y,et al.Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy:a meta-analysis［J］.Translational Lung Cancer Research,2019,8(3):214-226.
[10]KIRIU T,YAMAMOTO M,NAGANO T,et al.The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer［J］.PLoS One,2018,13(2):e0193018.
[11]GUBENS MA.NCCN guidelines updates:New immunotherapy strategies for improving outcomes in non-small cell lung cancer［J］.Journal of the National Comprehensive Cancer Network,2019,17(5.5):574-578.
[12]陈冠璇,宋现让.肺癌PD1/PD-L1免疫检查点治疗疗效预测标志物［J］.中国肺癌杂志,2018,21(9):697-702. CHEN GX,SONG XR.Predictive markers for treating efficacy of PD-1/PD-L1 inhibitors in patients with lung cancer［J］.Chinese Journal of Lung Cancer,2018,21(9):697-702.
[13]TANIZAKI J,HARATANI K,HAYASHI H,et al.Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab［J］.Journal of thoracic oncology：official publication of the International Association for the Study of Lung Cancer,2018,13(1):97-105.
[14]DUNN GP,OLD LJ.The immunobiology of cancer immunosurveillance and immunoediting［J］.Immunity,2004,21(2):137-148.
[15]LI X,LYU Q,FENG Y,et al.Interleukin-33,a potential cytokine expressed in tumor microenvironment involves in antitumor immunotherapy through facilitates CD8 T cells［J］.Journal of Interferon & Cytokine Research:the Official Journal of the International Society for Interferon and Cytokine Research,2018,38(11):491-499.
[16]SPIEGEL A,BROOLS MW,HOUSHYAR S,et al.Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells［J］.Cancer Discovery,2016,6(6):630-649.
[17]HOUGHTON AM,RZYMKIEWICZ DM,JI H,et al.Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth［J］.Nature Medicine,2010,16(2):219-223.
[18]GRUNWALD B,VANDOOREN J,LOCATELLI E,et al.Corrigendum to "matrix metalloproteinase-9(MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer［J］.Journal of Controlled Release,2016,239:39-48.
[19]杨童磊，刘涛，马琼，等.肿瘤相关中性粒细胞促进人骨肉瘤细胞SOSP-9607迁移及其作用机制［J］.现代肿瘤医学，2018,26（06）：813-817. YANG TL,LIU T,MA Q,et al.Tumor associated neutrophils promote the migration of human osteosarcoma cells SOSP-9607 and its mechanism［J］.Modern Oncology，2018,26（06）：813-817.
[20]SZNOL M.Antagonist antibodies to PD-1 and B7-H1(PD-L1) in the treatment of advanced human cancer-response［J］.Clinical cancer research：an Official Journal of the American Association for Cancer Research,2013,19(19):5542.

Memo

Memo:
-
Last Update: 2021-12-02